USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Emerging Non-opiod Pharmaceuticals for Pain Management
Emerging Non-opiod Pharmaceuticals for Pain Management
Emerging narcotic-free therapies
RELEASE DATE
27-May-2020
27-May-2020
REGION
Global
Global
Research Code: D97A-01-00-00-00
SKU: HC03297-GL-TR_24422
$4,950.00
Special Price $3,712.50 save 25 %
In stock
SKU
HC03297-GL-TR_24422
Description
The research provides technological advances and insights across non-opioid pharmaceuticals for the management of pain. Key application areas explored in the research include neuropathic pain, migrane, post-surgical pain, cancer pain, chronic pain and migraine. The research encompasses technological advances across Nav1.7 inhibitors, Calcitonin Gene-related peptide inhibitors, Platelet rich plasma therapy, Ditans, Hydrogel therapy, and stem cell therapy among several others.The research also provides competitive intelligence across emerging innovators in this space, while provide insights across the patent landscape for non-narcotic pain therapy.
Table of Contents
1.1 Key Findings
1.2 Analysis Framework: Frost & Sullivan’s Core Value
1.3 Research Methodology
2.1 Global Non-opioid Market
2.2 NSAIDs Continue to be Important for Pain Treatment
2.3 Types of Non-opioid Pharmaceuticals
2.4 Categories of Non-opioids in Development for Pain Management
2.4.1 Recently Approved Monoclonal Antibodies for Pain Management
2.5 Emerging Non-opioid Analgesics
2.6 Advanced Academic Researches in Pain Therapy
2.6 Advanced Academic Researches in Pain Therapy (continued)
3.1 Innovation Radar of Emerging Technologies
3.2 Summary of the Scoring Methodology
3.2.1 QBioMed
3.2.1 QBioMed (continued)
3.2.2 Centrexion Therapeutics
3.2.2 Centrexion Therapeutics (continued)
3.2.3 Concentric Analgesics
3.2.3 Concentric Analgesics (continued)
3.2.4 Xenon Pharmaceuticals
3.2.4 Xenon Pharmaceuticals (continued)
3.2.5 KinetaBio
3.2.5 KinetaBio (continued)
3.2.6 Navega Therapeutics
3.2.6 Navega Therapeutics (continued)
3.2.7 Tetra Biopharma
3.2.7 Tetra Biopharma (continued)
3.2.8 Vapogenix
3.2.8 Vapogenix (continued)
4.1 Pain Therapy Innovations Roadmap
4.2 Growth Opportunity 1: R&D Investment
4.3 Growth Opportunity 2: Technology Convergence
4.4 Conclusion
5.1 IP Overview in Non-opioid Pharmaceuticals
5.2 Leading Pharmaceutical Patent Holders
5.3 Patent Scenario
5.3Patent Scenario
6.1 List of Non-opioids in the Market
6.2 Key Industry Contacts
6.2 Key Industry Contacts (continued)
Legal Disclaimer
Popular Topics
The research provides technological advances and insights across non-opioid pharmaceuticals for the management of pain. Key application areas explored in the research include neuropathic pain, migrane, post-surgical pain, cancer pain, chronic pain and migraine. The research encompasses technological advances across Nav1.7 inhibitors, Calcitonin Gene-related peptide inhibitors, Platelet rich plasma therapy, Ditans, Hydrogel therapy, and stem cell therapy among several others.The research also provides competitive intelligence across emerging innovators in this space, while provide insights across the patent landscape for non-narcotic pain therapy.
| No Index | No |
|---|---|
| Podcast | No |
| Author | Neeraja Vettekudath |
| Industries | Healthcare |
| WIP Number | D97A-01-00-00-00 |
| Is Prebook | No |